Why ClearPoint Neuro, Inc.’s (CLPT) Stock Is Up 6.20%
As of Friday, August 07, ClearPoint Neuro, Inc.’s CLPT share price has surged by 6.20%, which has investors questioning if this is right time to sell.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Cynthia McLaughlin
Tudor Pop
Jenna Brashear
Cynthia McLaughlin
| Share Statistics | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $463.4 | $407.7 | 36% |
|
| Shares Out (Mil) | 30.2 | 41.3 | 37% |
|
| Institutional Ownership | 87.9% | 81.4% | 56% |
|
| Float (Mil) | 26.3 | 34.9 | 34% |
|
| Beta | 1.27 | 0.88 | 75% |
|
| Avg Daily Volume (000s) | 440 | 412 | 56% |
|
| Price Change (52-week) |
45.2% | 64.8% | 77% |
|
| Growth | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 23.7% | 11.8% | 85% |
|
| Net Income (5yr) | (30.3%) | (6.0%) | 13% |
|
| EPS (5yr) | (16.1%) | 10.4% | 17 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.9% | (16.2%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.323) | ($1.323) | ($1.107) | |
| Month Ago EPS | ($0.263) | ($1.113) | ($0.940) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 3 | |
| Three Months Ago EPS | ($0.263) | ($1.113) | ($0.940) | |
| Year/Year Chg | (14.1%) | 46.7% | 8.6% | |
| Financials | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $42 | $119 | 19% |
|
| Net Income (TTM) (Mil) | ($35) | ($9) | 19% |
|
| EPS (TTM) | ($1.182) | ($0.400) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($30) | ($3) | 12% |
|
| Net Cash Flow (TTM) (Mil) | ($11) | $1 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $64 | $21 | 41% |
|
| Enterprise Value (Q1) (Mil) | $436 | $427 | 33% |
|
| Valuation | CLPT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 43.40 | 3.06 | 98% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 62.6% | 58.9% | 75% |
|
| Net Margin | (81.8%) | (6.9%) | 9% |
|
| ROA | (46.2%) | (12.7%) | 12% |
|
| ROE | (226.5%) | (13.1%) | 4% |
|
| Liabilities to Assets | 87.6% | 46.0% | 81% |
|
| F-Score | 2 | 4 | 7% |
|
ClearPoint Neuro, Inc. did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors